title: Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK.
abstract: OBJECTIVE
  To perform a masked study to determine whether resolvin E1 (RvE1), a lipid-derived immunomodulator, could regulate the development of corneal haze and opacity-related myofibroblasts after opacity-generating high correction photorefractive keratectomy (PRK) in rabbits.
  
  
  METHODS
  Three groups of eight rabbits each were included in the study. Nine diopter (D) PRK for myopia was performed in each test cornea, and the eyes were treated with 30 µl of topical solution every 4 h (six times a day) for 5 days starting immediately after PRK. Group 1 was treated with 0.1% RX-10045, a prodrug of an RvE1 analog; group 2 was treated with 0.01% RX-10045; and group 3 was treated with vehicle control solution. At 1 month after PRK, haze was graded at the slit-lamp by a masked observer. Immunohistochemistry for α-smooth muscle actin (SMA) was performed on the central cornea of each test eye to determine the anterior stromal myofibroblast density.
  
  
  RESULTS
  Corneal opacity was significantly lower in the 0.1% RX-10045 group, but not the 0.01% RX-10045 group, compared to the vehicle control group (p=0.029), at 1 month after -9.0D PRK. At 1 month after -9.0D PRK, SMA+ myofibroblast densities in the anterior stroma were not statistically significantly different among the three groups, although a trend toward lower myofibroblast generation was noted in the 0.1% RX-10045 group.
  
  
  CONCLUSIONS
  Topical 0.1% RX-10045, a prodrug of an RvE1 analog, reduces corneal opacity after haze-generating PRK in rabbits. Further studies are needed to determine the precise points at which RvE1 decreases corneal opacity after injury.
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Andre A M
authors.initials: AA
authors.lastname: Torricelli
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Abirami
authors.initials: A
authors.lastname: Santhanam
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Vandana
authors.initials: V
authors.lastname: Agrawal
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Wilson
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D065306:Corneal Injuries / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D003318:Corneal Opacity / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D058628:Myofibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011355:Prodrugs / Q000008:administration & dosage; D011817:Rabbits
chemical_list: D000199:Actins; D009883:Ophthalmic Solutions; D011355:Prodrugs; C000603302:isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate; D015118:Eicosapentaenoic Acid; C499823:5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid